Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 4/20 | 0.63 |
| ▸ | CNR1 | P21554 | 3/20 | 0.63 |
| ▸ | HTR7 | P34969 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7550775 | 0.88 | CNR2 (0.62) | CNR2CNR1HTR7HTTKMT2A | |
| SCHEMBL7550761 | 0.85 | CNR2 (0.67) | CNR2CNR1HTR7HTTKMT2A | |
| SCHEMBL7556631 | 0.82 | CNR1 (0.64) | CNR2CNR1KMT2AKCNH2HTR4 | |
| SCHEMBL9323662 | 0.82 | CNR1 (0.53) | CNR2CNR1HTR7HTTKMT2A | |
| SCHEMBL16173745 | 0.81 | CNR2 (0.66) | CNR2CNR1KMT2ACYP3A4CYP2D6 | |
| SCHEMBL15882124 | 0.81 | ROCK1 (0.53) | CNR2CNR1KMT2ATSHRCYP1A2 | |
| SCHEMBL5438502 | 0.79 | TSHR (0.54) | CNR2CNR1KMT2AMAPTTSHR | |
| SCHEMBL31429522 | 0.79 | TSHR (0.54) | CNR2CNR1KMT2AMAPTTSHR | |
| SCHEMBL13502767 | 0.78 | CNR2 (1.00) | CNR2CNR1KMT2AALDH1A1KCNH2 | |
| SCHEMBL15882181 | 0.78 | HTR4 (0.48) | CNR2CNR1TSHRCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050107399-A1 | Cytokine inhibitors | KEMIA, INC. | 2005-05-19 | — | — | US | claimed |
| EP-1670787-B1 | CYTOKINE INHIBITORS | ITHERX PHARMA INC (US) | 2012-05-30 | — | — | EP | disclosed |
| US-7919617-B2 | Cytokine inhibitors | iTherX Pharmaceuticals Inc. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7897599-B2 | Cytokine inhibitors | iTherX Pharmaceuticals Inc. (US) | 2011-03-01 | — | — | US | disclosed |
| US-20100273797-A1 | ALPHA-KETOAMIDES AND DERIVATIVES THEREOF | ITHERX PHARMACEUTICALS, INC. | 2010-10-28 | — | — | US | disclosed |
| US-7749999-B2 | Alpha-ketoamides and derivatives thereof | ITHERX PHARMACEUTICALS, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-20100093734-A1 | CYTOKINE INHIBITORS | ITHERX PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100093735-A1 | CYTOKINE INHIBITORS | ITHERX PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| EP-2035005-A2 | THERAPY USING CYTOKINE INHIBITORS | Kemia, INC. (US) | 2009-03-18 | — | — | EP | disclosed |
| WO-2007146712-A2 | THERAPY USING CYTOKINE INHIBITORS | KEMIA, INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007058990-A2 | THERAPY USING CYTOKINE INHIBITORS | KEMIA, INC. (US) | 2007-05-24 | — | — | WO | disclosed |
| US-20050107399-A1 | Cytokine inhibitors | KEMIA, INC. | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107399-A1 | Cytokine inhibitors | TNF, IL1RN, IL1A | CNR2 2697/4885CNR1 2862/4885HTR7 4233/4885 |
| US-20100093734-A1 | CYTOKINE INHIBITORS | TNF, IL1RN, IL1A | CNR2 2697/4885CNR1 2862/4885HTR7 4233/4885 |
| US-20100273797-A1 | ALPHA-KETOAMIDES AND DERIVATIVES THEREOF | TNF, IL1A, IL1B | CNR2 221/4885CNR1 375/4885HTR7 4375/4885 |
| US-20100093735-A1 | CYTOKINE INHIBITORS | TNF, IL1RN, IL1A | CNR2 2697/4885CNR1 2862/4885HTR7 4233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.